BridgeBio Pharma Inc

NASDAQ:BBIO  
53.66
+2.94 (+5.80%)
Products

BridgeBio Pharma, Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma

Published: 12/01/2020 12:48 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma and Affiliate Qed Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma.
Bridgebio Pharma Inc - New Drug Application (nda) for Infigratinib Granted Priority Review Designation.